Abstract
The American Society of Addiction Medicine (ASAM) has for months not taken any position on the “x the x‐waiver” movement, which would deregulate the prescription of buprenorphine, eliminating the provisions of the Drug Addiction Treatment Act of 2000 (DATA 2000), which require prescribers to have training and to have a special registration with the Drug Enforcement Administration (DEA). Last week, however, ASAM came out with this: It agrees with making buprenorphine more accessible by getting rid of the x‐waiver.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
